Last reviewed · How we verify

Ped3CB — Competitive Intelligence Brief

Ped3CB (Ped3CB) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sodium-potassium pump inhibitor. Area: Cardiovascular.

phase 3 Sodium-potassium pump inhibitor Na+/K+-ATPase Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Ped3CB (Ped3CB) — Baxter Healthcare Corporation. Ped3CB is a small molecule that acts as a selective inhibitor of the sodium- potassium pump.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Ped3CB TARGET Ped3CB Baxter Healthcare Corporation phase 3 Sodium-potassium pump inhibitor Na+/K+-ATPase
EG-007 EG-007 Evergreen Therapeutics, Inc. phase 3 sodium-potassium pump inhibitor sodium-potassium pump

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sodium-potassium pump inhibitor class)

  1. Baxter Healthcare Corporation · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ped3CB — Competitive Intelligence Brief. https://druglandscape.com/ci/ped3cb. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: